German Manager Magazin: Stellantis with new boss: Antonio Filosa from Italy becomes the new CEO004222

After the then CEO Carlos Tavares (66) was fired at the end of last year, Stellantis had checked a number of internal and external candidates, according to “Corriere della Sera”. According to the newspaper, the Supervisory Board also considered a shopping manager Maxim Picat (51) and the former autonation CEO Mike Manley (61). Filosa was… Continue reading German Manager Magazin: Stellantis with new boss: Antonio Filosa from Italy becomes the new CEO004222

Jeep India’s Wrangler Willys Limited Edition Sells Out Within Weeks

Jeep India announced that its Wrangler Willys Limited Edition has completely sold out just weeks after launch. The limited-run model, designed as a tribute to the brand’s heritage, generated significant interest among off-road enthusiasts across the country. Kumar Priyesh, Business Head and Director of Automotive Brands at Jeep India, attributed the success to customer loyalty… Continue reading Jeep India’s Wrangler Willys Limited Edition Sells Out Within Weeks

@FCA: Stellantis Announces Antonio Filosa – 25-Year Veteran of the Company – to Be Its New Chief Executive Officer

Antonio Filosa – who currently serves as Chief Operating Officer for the Americas and Chief Quality Officer – to assume CEO powers on June 23  May 28, 2025 , Amsterdam –  Stellantis N.V. (the “Company”) announces that its Board of Directors (the “Board”) has unanimously selected Antonio Filosa as its new Chief Executive Officer following a… Continue reading @FCA: Stellantis Announces Antonio Filosa – 25-Year Veteran of the Company – to Be Its New Chief Executive Officer

TfL plots congestion charge increase to £18 per day

Transport for London (TfL) has proposed raising the congestion charge for driving into the capital during peak hours to £18 per day. TfL has called for public views on the hike – up from the current £15 per day – which has been mooted to come into effect from 2 January 2026. It would mark… Continue reading TfL plots congestion charge increase to £18 per day

New Vauxhall Frontera Electric gets 4×4 makeover

Vauxhall has hinted at a more rugged version of the incoming Frontera with a new concept car that turns the conventional electric crossover into a trail-hunting 4×4. Named the Vauxhall Frontera Gravel and based on the electric version of the family car, it gains several key elements aimed at helping it tackle the wilderness. Up… Continue reading New Vauxhall Frontera Electric gets 4×4 makeover

Trzy marki Linglong zaznaczają swoją obecność na Autopromotec 2025

BOLONIA, Włochy, 27 maja 2025 r. /PRNewswire/ – Odbyło się uroczyste otwarcie targów Autopromotec 2025. Firma Linglong Tire zaprezentowała swoje główne marki europejskie: „LINGLONG”, „CROSSWIND” i „LEAO” i wprowadziła na rynek międzynarodowy liczne produkty, zwracając uwagę na swój znaczny udział w rynku europejskim i przywództwo technologiczne. Główne produkty prezentowane na targach: przywództwo dzięki zaawansowanym parametrom… Continue reading Trzy marki Linglong zaznaczają swoją obecność na Autopromotec 2025

First pictures: Volvo XC70 PHEV offers 112 miles of EV range

The new Volvo XC70 plug-in hybrid has been outed ahead of its official debut, courtesy of new images published by China’s Ministry of Industry and Information Technology (MIIT). Earlier preview images gave a good idea of the reborn XC70’s design, confirming that it would morph from high-riding estate into full-blown SUV, but these new images… Continue reading First pictures: Volvo XC70 PHEV offers 112 miles of EV range

Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ — Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a… Continue reading Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ — Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a… Continue reading Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection